Gene G. Kinney Sells 376 Shares of Prothena Co. plc (NASDAQ:PRTA) Stock

Posted by MarketBeat News on Aug 1st, 2022

Prothena Co. plc (NASDAQ:PRTA – Get Rating) CEO Gene G. Kinney sold 376 shares of Prothena stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $32.00, for a total transaction of $12,032.00. Following the completion of the sale, the chief executive officer now directly owns 12,793 shares in the company, valued at approximately $409,376. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Prothena Stock Performance

Shares of PRTA stock opened at $31.06 on Monday. The stock’s fifty day moving average is $28.04 and its two-hundred day moving average is $31.75. The firm has a market capitalization of $1.45 billion, a P/E ratio of 25.46 and a beta of 1.30. Prothena Co. plc has a fifty-two week low of $21.06 and a fifty-two week high of $79.75.

Prothena (NASDAQ:PRTA – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.07. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.23 million. Prothena had a return on equity of 16.02% and a net margin of 33.45%. On average, equities analysts forecast that Prothena Co. plc will post -2.53 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Marshall Wace LLP raised its holdings in shares of Prothena by 211.6% during the 4th quarter. Marshall Wace LLP now owns 214,691 shares of the biotechnology company’s stock worth $10,605,000 after acquiring an additional 145,799 shares during the period. Ensign Peak Advisors Inc raised its holdings in shares of Prothena by 76.0% during the 4th quarter. Ensign Peak Advisors Inc now owns 38,997 shares of the biotechnology company’s stock worth $1,927,000 after acquiring an additional 16,835 shares during the period. Robeco Institutional Asset Management B.V. raised its holdings in shares of Prothena by 29.3% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 21,932 shares of the biotechnology company’s stock worth $1,084,000 after acquiring an additional 4,972 shares during the period. GSA Capital Partners LLP raised its holdings in shares of Prothena by 267.2% during the 4th quarter. GSA Capital Partners LLP now owns 13,259 shares of the biotechnology company’s stock worth $655,000 after acquiring an additional 9,648 shares during the period. Finally, Barclays PLC raised its holdings in shares of Prothena by 171.0% during the 4th quarter. Barclays PLC now owns 48,880 shares of the biotechnology company’s stock worth $2,415,000 after acquiring an additional 30,844 shares during the period. Hedge funds and other institutional investors own 92.64% of the company’s stock.

Analysts Set New Price Targets

Separately, JMP Securities dropped their price target on shares of Prothena from $77.00 to $50.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 25th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $70.33.

Prothena Company Profile

(Get Rating)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.